Drug Trial Radar · NCT07816380
A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
216
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
Dec 30, 2028
Study completion Dec 30, 2029
Sponsor
- Lead sponsor
- Guangzhou JOYO Pharma Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 11, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, open-label, multicenter phase III study to evaluate the efficacy and safety of JYP0322 compared with crizotinib in previously untreated ROS1-positive locally advanced or metastatic non-small cell lung cancer.
Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
JYP0322 TabletsDrug
Oral administration, 150 mg each dose, three times daily (TID), continuous dosing.
Crizotinib CapsulesDrug
Oral administration, 250 mg twice daily (BID), continuous dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR/BIRC) per RECIST v1.1Time frame: From randomization to the date of first documented radiographic disease progression or death from any cause, whichever occurs first, assessed up to approximately 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.